键凯科技：拐点已至，期待未来

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expectation that the company's stock price will exceed the benchmark index by more than 20% within the next 6-12 months [42][46]. Core Insights - The report highlights the high barriers to entry in the polyethylene glycol (PEG) modification technology sector, with few companies globally possessing advanced synthesis and modification capabilities [1]. - The domestic PEG industry is still in its early stages compared to international counterparts, with ongoing exploration and development [2]. - The global PEG-modified drug market has reached a certain scale, while the domestic market is just beginning to develop [7]. - The report notes a significant increase in the number of companies engaged in PEG-modified drug research and clinical trials in China, with approximately 45+ companies reported as of December 31, 2023 [11]. - The report discusses the broad prospects for PEG-modified drugs in light of the ongoing national procurement policies, which have led to substantial price reductions in generic drugs [12]. Summary by Sections Company Overview - The report provides a detailed overview of several companies involved in PEG technology, including Xiamen Sinobang Biological Technology Co., Ltd., Jiaxing Bomei Biotechnology Co., Ltd., and Beijing Kaizheng United Pharmaceutical Technology Co., Ltd., highlighting their focus areas and product offerings [5]. Market Dynamics - The report outlines the competitive landscape of the long-acting drug market, emphasizing the limited number of approved long-acting G-CSF products in China, which presents opportunities for growth [54][55]. - It also discusses the increasing sales of overseas medical device products, with a reported growth of 21.48% year-on-year in 2023 [33]. Financial Projections - The company is projected to achieve revenues of CNY 368 million, CNY 459 million, and CNY 559 million from 2024 to 2026, respectively, with net profits expected to reach CNY 142 million, CNY 178 million, and CNY 220 million in the same period [42][72]. - The report anticipates a gradual improvement in the company's performance, driven by the launch of new products by downstream clients [42]. Product Development - The report highlights the successful clinical trial progress of the PEG-modified irinotecan and the development of new medical aesthetic products, indicating a promising future for the company's product pipeline [34][39]. - It also mentions the company's proprietary PEG cross-linked sodium hyaluronate gel project, which has received regulatory acceptance and is advancing through clinical trials [39][68].